01/25/23 8:30 AMNasdaq : ALLO clinical trialhigh shortAllogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung CancerAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology companyRHEA-AIneutral
01/24/23 8:30 AMNasdaq : ALLO clinical trialhigh shortAllogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple MyelomaAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology companyRHEA-AIneutral
01/17/23 4:05 PMNasdaq : ALLO conferenceshigh shortAllogene Therapeutics Announces Participation in Two Upcoming Investor ConferencesAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investorRHEA-AIneutral
01/04/23 8:30 AMNasdaq : ALLO conferenceshigh shortAllogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that David Chang, M.D., Ph.D., President, ChiefRHEA-AIneutral
01/03/23 8:00 AMNasdaq : ALLO managementhigh shortAllogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology companyRHEA-AIneutral
11/29/22 3:30 PMNasdaq : ALLO high shortAllogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ PlatformHematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL) One-Time Cell Dosing with Proprietary Lymphodepletion (SingleRHEA-AIneutral
11/10/22 9:00 AMNasdaq : ALLO high shortAllogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of CancerPromising Preclinical Data Highlights a Simple One-Step Gene Editing Strategy to Prevent the Rejection of AlloCAR T™ Cells by Host T Cells and NK Cells Cloaking Approach Demonstrates Superiority to B2M Knock Out in a Syngeneic In Vivo Model Proprietary Approach Is One of Several Next GenerationRHEA-AInegative
11/09/22 8:30 AMNasdaq : ALLO conferenceshigh shortAllogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor ConferencesAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer will host a Research & Development Showcase to provide a comprehensiveRHEA-AIneutral
11/03/22 9:04 AMNasdaq : ALLO clinical trialhigh shortAllogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of HematologyALLO-715, an Allogeneic BCMA CAR T Candidate Dosed with an ALLO-647 Based Lymphodepletion Regimen, Continues to Demonstrate a Promising Clinical Profile A Company Sponsored R&D Showcase on November 29, 2022 will Discuss Updated Data With Single Dose ALLO-715 and Future Development Plans SOUTH SANRHEA-AIneutral
11/02/22 4:02 PMNasdaq : ALLO earningshigh shortAllogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D ShowcaseInitiated the Industry’s First Allogeneic CAR T Phase 2 Trial ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501A Readiness Activities Underway for Initiation of the EXPAND Trial,RHEA-AIneutral